Method for treating retroviral infections
AssigneeUniroyal Chemical Company, Inc.
InventorsJohn A. Lacadie, James B. Pierce
Life of this patent
Estimating the term…
Abstract
Compositions and methods of treating a retroviral infection in an afflicted host and/or inhibiting replication of a retrovirus involve administering a therapeutically effective amount of the following compound of formula I: A-L-B (I) wherein A is a substituted or unsubstituted aryl compound, substituted or unsubstituted piperidyl, or substituted or unsubstituted thiopheneyl; L is sulfonyl, sulfinyl or thio; and B is a substituted or unsubstituted aromatic nitrogen containing heteroaryl compound; or pharmacologically acceptable acid-addition and base-addition salts thereof.
Claims10
A method of treating an infection by HCMV or HHV in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound represented by the following formula:
- A-L-B
- or a pharmaceutically acceptable acid-addition or base-addition salt thereof;
- wherein:
- component A is a functional group of the following formula:
- wherein Z is H, Cl, cyano, alkyl having from 1 to 15 carbon atoms, alkoxyalkyl having 2 or 3 carbon atoms;
- Y is H or a double bond to a carbon which is attached to R;
- and R is phenyl, biphenyl, benzyl, naphthyl, anthranyl, pyridyl, thienyl, quinolyl, isoquinolyl or phenyl substituted with 1 to 5 substituents which may be the same or different, the substituents being selected from the group consisting of lower alkyl having from 1 to 5 carbon atoms, halogen, nitro, methoxy, ethoxy, benzyloxy, methylenedioxy, 2,2-dichlorocyclopropyl, trifluoromethyl, methylsulfonyl, cyano and phenoxy;
- component L is sulfonyl, sulfinyl or thio;
- and,
- component B is a functional group of the following formula:
- wherein n is 1, R1 and R2 may be the same or different and are H, halogen, lower alkyl having from 1 to 4 carbon atoms, hydroxy, or nitro.
A method of inhibiting the replication of HCMV or HHV, the method comprising contacting the HCMV or HHV with an effective amount a compound represented by the following formula:
- A-L-B
- or a pharmaceutically acceptable acid-addition or base-addition salt thereof;
- wherein:
- component A is a functional group of the following formula:
- wherein Z is H, Cl, cyano, alkyl having from 1 to 15 carbon atoms, alkoxyalkyl having 2 or 3 carbon atoms;
- Y is H or a double bond to a carbon which is attached to R;
- and R is phenyl, biphenyl, benzyl, naphthyl, anthranyl, pyridyl, thienyl, quinolyl, isoquinolyl or phenyl substituted with 1 to 5 substituents which may be the same or different, the substituents being selected from the group consisting of lower alkyl having from 1 to 5 carbon atoms, halogen, nitro, methoxy, ethoxy, benzyloxy, methylenedioxy, 2,2-dichlorocyclopropyl, trifluoromethyl, methylsulfonyl, cyano and phenoxy;
- component L is sulfonyl, sulfinyl or thio;
- and,
- component B is a functional group of the following formula:
- wherein n is 1, R1 and R2 may be the same or different and are H, halogen, lower alkyl having from 1 to 4 carbon atoms, hydroxy, or nitro.
A method of treating an HCMV infection in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound selected from the group consisting of 2-[1-(2,5-dimethylphenyl)octylsulfonyl]pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)propyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[(9-anthryl)methylsulfonyl]pyridine-N-oxide, 2-[4-((1,1dimethyl)propyl)phenyl)methylsulfonyl]pyridine-N-oxide, and pharmaceutically acceptable acid-addition and base-addition salts thereof.
A method of treating an HHV-6 infection in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound selected from the group consisting of 2-[(2,5-dimethylphenyl)methylsulfonyl]pyridine-N-oxide, and 2-(phenylmethylsulfonyl)pyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.
Dependencies are inferred from the claim text.